Clopidogrel Bisulfate Tablets 75mg GMP Medicine

Category:Active Pharmaceutical Ingredients
Product Name:Clopidogrel Bisulfate Tablets 75mg GMP Medicine
CAS No.:NA
Standard:In-house Standards
Price(USD):Negotiable
Company:NINGBO VOICE BIOCHEMIC CO., LTD.

Basic Info
  • Grade: pharmaceutical grade

    Factory Location: Ningbo

    Main Sales Markets: orth America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: no

    Therapeutic indications Prevention of vascular ischaemia associated with secondary atherothrombotic events (MI,stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. Acute coronary syndrome Clopidogrel is indicated in combination with aspirin for patients with: • Unstable angina or non-ST elevation MI. Clopidogrel is indicated for early and long-term reduction of atherothrombotic events (myocardial infarction, stroke, vascular death and refractory ischaemia) whether or not patients undergo cardiac revascularisation (surgical or PCI, with or without stent). • ST-segment elevation acute myocardial infarction. In this population, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke. Dose and method of administration Clopidogrel should be taken once a day with or without food. Adults Generally, clopidogrel should be given as a single daily dose of 75 mg. In patients with acute coronary syndrome: • unstable angina or non-ST elevation myocardial infarction - clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued long-term at 75 mg once a day (with aspirin 75 mg-325 mg daily). • ST elevation acute myocardial infarction - clopidogrel treatment should be given as a single daily dose of 75 mg initiated with or without a 300 mg loading dose in combination with aspirin and with or without thrombolytics. No dosage adjustment is necessary for either elderly patients or patients with renal impairment Children and adolescents Safety and efficacy in subjects below the age of 18 have not been established.
Send your message to this supplier
  • From:
  • To:
    NINGBO VOICE BIOCHEMIC CO., LTD.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service